Skip to main content
SpringerLink
Log in

Klinische Empfehlungen. Gastrointestinale Stromatumore: Empfehlungen zu Diagnose, Behandlung und Nachsorge in Österreich

Gastrointestinal stromal tumors: recommendations for diagnosis, treatment and aftercare in Austria

  • Themenschwerpunkt
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

Diagnosis and treatment of gastrointestinal stromal tumors (GIST) requires an interdisciplinary treatment approach. This strategy should be reflected by the content of this article. Austrian representatives of 'GIST relevant' specialties authored this publication on a consensual base. This manuscript should be regarded as a guideline for 'GIST involved' colleagues in Austria.

Zusammenfassung

Die Diagnose und Behandlung von GIST bedarf eines interdisziplinären Ansatzes. Dieser Gedanken wiederspiegelt den Inhalt dieser Publikation. Österreichische Vertreter von für Diagnose und Behandlung von GIST Patienten relevanten Fachdisziplinen verfassten dieses Manuskript konsensuell. Die vorliegende Arbeit soll als Leitfaden für die in 'GIST involvierte' Kollegenschaft in Österreich dienen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer, 75(1 Suppl): 154–170, 1995

    Article  PubMed  CAS  Google Scholar 

  • Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunothistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 438(1): 1–12, 2001

    Article  PubMed  CAS  Google Scholar 

  • Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer, 103(4): 821–829, 2005

    Article  PubMed  Google Scholar 

  • Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973–2004, and current diagnosis and therapy. Int J Oncol, 33(6): 1121–1131, 2008

    PubMed  Google Scholar 

  • Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol, 29(10): 1373–1381, 2005

    Article  PubMed  Google Scholar 

  • Antonescu CR. Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol, 23(2): 63–69, 2006

    Article  PubMed  Google Scholar 

  • Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol, 30(1): 90–96, 2006

    Article  PubMed  Google Scholar 

  • Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 22(18): 3813–3825, 2004

    Article  PubMed  CAS  Google Scholar 

  • Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer, 38(Suppl 5): S37–S38, 2002

    Article  PubMed  Google Scholar 

  • Aaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol, 23(2): 120–129, 2006

    Article  Google Scholar 

  • Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int, 56(1): 1–9, 2006

    Article  PubMed  CAS  Google Scholar 

  • Montemurro M, et al. Diagnose und Behandlung von GIST in der Schweiz. Schweizer Med. Forumm, 8(30–31): 544–549, 2008

    Google Scholar 

  • Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of GIST: increasing significance for risk assessment and effective targeted therapy. Virchows Arch, 451: 743–749, 2007

    Article  PubMed  Google Scholar 

  • Dow N, Giblen G, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol, 23(2): 111–119, 2006

    Article  PubMed  Google Scholar 

  • Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol, 21(Suppl 2): S31–S36, 2008

    Article  PubMed  CAS  Google Scholar 

  • Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol, 3: 557–586, 2008

    Article  PubMed  CAS  Google Scholar 

  • Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 29(1): 52–68, 2005

    Article  PubMed  Google Scholar 

  • Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 33(5): 459–465, 2002

    Article  PubMed  Google Scholar 

  • Miettinen M, Lasota J. Gastrointestinal stromal tumors. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 130(10): 1466–1478, 2006

    PubMed  CAS  Google Scholar 

  • Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 39(10): 1411–1419, 2008

    Article  PubMed  Google Scholar 

  • Katenkamp D, Katenkamp K. Gastrointestinale Stromatumoren. Diagnose und Malignitätseinschätzung. Chirurg, 79(7): 625–629, 2008

    Article  PubMed  CAS  Google Scholar 

  • Akahoshi K, Sumida Y, Matsui N, Oya M, Akinaga R, Kubokawa M, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. World J Gastroenterol, 13(14): 2077–2082, 2007

    PubMed  Google Scholar 

  • Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am, 89(1): 217–233, 2009

    Article  PubMed  Google Scholar 

  • Raut CP, Ashley SW. How I do it: surgical management of gastrointestinal stromal tumors. J Gastrointest Surg, 12: 1592–1599, 2008

    Article  PubMed  Google Scholar 

  • Langer C, Schüler P, Becker H, Liersch T. Gastrointestinale Stromatumore aus chirurgischer Sicht. Chirurg, 79(7): 644–649, 2008

    Article  PubMed  CAS  Google Scholar 

  • Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery, 139(4): 484–492, 2006

    Article  PubMed  Google Scholar 

  • Pitsinis V, Khan AZ, Cranshaw I, Allum WH. Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. Hepatogastroenterology, 54(74): 606–608, 2007

    PubMed  CAS  Google Scholar 

  • Alam I, Kheradmand F, Alam S, Jamil A, Wilson I, Hurley M. Laparoscopic management of acutely presenting gastrointestinal stromal tumors: a study of 9 cases and review of literature. J Laparoendosc Adv Surg Tech A, 17(5): 626–633, 2007

    Article  PubMed  Google Scholar 

  • Privette A, McCahill L, Borrazzo E, Single RM, Zubarik R. Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumor location. Surg Endosc, 22(2): 487–494, 2008

    Article  PubMed  CAS  Google Scholar 

  • Catena F, Di Battista M, Fusaroli P, Ansaloni L, Di Scioscio V, Santini D, et al. Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review. J Gastrointest Surg, 12(3): 561–568, 2008

    Article  PubMed  Google Scholar 

  • Sexton JA, Pierce RA, Halpin VJ, Eagon JC, Hawkins WG, Linehan DC, et al. Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc, 22(12): 2583–2587, 2008

    Article  PubMed  Google Scholar 

  • Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 29(1): 52–68, 2005

    Article  PubMed  Google Scholar 

  • Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol, 14(1): 14–24, 2007

    Article  PubMed  Google Scholar 

  • Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol, 99(1): 42–47, 2009

    Article  PubMed  CAS  Google Scholar 

  • Heinrich MC, Owzar K, Corless CI, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia Group B and Southwest Oncology Group. J Clin Oncol, 26(33): 5360–5367, 2008

    Article  PubMed  CAS  Google Scholar 

  • Van den Abbeele AD. The lessons of GIST – PET and PET/CT: a new paradigm for imaging. Oncologist, 13(Suppl 2): 8–13, 2008

    Article  PubMed  Google Scholar 

  • Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol, 98(1): 27–33, 2008

    Article  PubMed  Google Scholar 

  • Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bümming P, Nilsson O, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumors (GIST). Br J Cancer, 96(11): 1656–1658, 2007

    Article  PubMed  CAS  Google Scholar 

  • ASCO 2008 abstract #8 (De Matteo). Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence. The U.S. Intergroup phase II trial ACOSOG Z9000

  • DeMatteo R, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet, 373(9669): 1097–1104, 2009

    Article  PubMed  CAS  Google Scholar 

  • Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D. Prospective multicentric randomized phase III study of imatinib patients with advanced GIST comparing unterruption vs. continuation of treatment beyond 1 year, the French Sarcoma Group. J Clin Oncol, 25: 1107–1113, 2007

    Article  PubMed  CAS  Google Scholar 

  • Scandinavian Sarcoma Group: Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST); http://www.clinicaltrials.gov/ct2/show/NCT00116935?term=SSGXVIII&rank=1

  • European Organization for Research and Treatment of Cancer, Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor. http://www.clinicaltrials.gov/ct2/show/NCT00103168?term=EORTC+62024&rank=1

  • European Organization for Research and Treatment of Cancer, Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor. http://www.clinicaltrials.gov/ct2/show/NCT00103168?term=EORTC+62024&rank=1

  • Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 295(1): 139–145, 2000

    PubMed  CAS  Google Scholar 

  • Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96(3): 925–932, 2000

    PubMed  CAS  Google Scholar 

  • Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347(7): 472–480, 2002

    Article  PubMed  CAS  Google Scholar 

  • Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 26(4): 620–625, 2008

    Article  PubMed  CAS  Google Scholar 

  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyroine kinase: S0033. J Clin Oncol, 26(4): 626–632, 2008

    Article  PubMed  CAS  Google Scholar 

  • Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004: 364(9440): 1127–1134

    Article  PubMed  CAS  Google Scholar 

  • Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J. GIST Meta-analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1,640 patients (pts). JCO, 25(18S): 10004, 2007

    Google Scholar 

  • Debiec-Rychter M, Sciot R, Le Cescne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 1093–1103, 2006

  • Demetri GD, Joensuu H. Systemic treatment of patients with GIST: current status and future opportunities. Eur J Cancer, (Suppl 6): 1–14, 2008

  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyroine kinase: S0033. J Clin Oncol, 26(4): 626–632, 2008

    Article  PubMed  CAS  Google Scholar 

  • Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 364(9440): 1127–1134, 2004.

    Article  PubMed  CAS  Google Scholar 

  • Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced GIST crossing over to a daily Imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer, 41(12): 1751–1757, 2005

    Article  PubMed  CAS  Google Scholar 

  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 26(4): 626–632, 2008

    Article  PubMed  CAS  Google Scholar 

  • Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer, 44(4): 501–509, 2008

    Article  PubMed  CAS  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 368(9544): 1329–1338, 2006

    Article  PubMed  CAS  Google Scholar 

  • George S, Blay JY, Casali PG, Le Cesne A, Stephanson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer, 2009. [Mar 10; epub ahaed of print]

  • Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov, 3(2): 88–99, 2008

    Article  PubMed  CAS  Google Scholar 

  • Reichardt P. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep, 10(4): 344–349, 2008

    Article  PubMed  CAS  Google Scholar 

  • Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. ESMO Guidelines Working Group: Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19(Supp 2): ii35–ii38, 2008

    Article  PubMed  Google Scholar 

  • Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, et al. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol, 134(5): 625–630, 2008

    Article  PubMed  CAS  Google Scholar 

  • Ruka W, Rutkowski P, Szawlowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, et al, Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol, 35(1): 87–91, 2009

    PubMed  CAS  Google Scholar 

  • NCCN Clinical Practice guidelines in oncology, soft tissue sarcome, v.1.2009; www.nccn.org

  • Sleijfer S, Wiemer E, Seynaeve C, Verweij J, et al. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist, 12(6): 719–726, 2007

    Article  PubMed  CAS  Google Scholar 

  • Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 26(33): 5352–5359, 2008

    Article  PubMed  CAS  Google Scholar 

  • Nilsson B, Nilsson O, Ahlmann H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then? Expert Opin Investig Drugs, 18(4): 457–468, 2009

    Article  PubMed  CAS  Google Scholar 

  • Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 25(13): 1753–1759, 2007

    Article  PubMed  Google Scholar 

  • Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol, 25(13): 1760–1764, 2007

    Article  PubMed  Google Scholar 

  • Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corles CL, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw, 5(Suppl 2): S1–S29, 2007

    PubMed  Google Scholar 

  • Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. ESMO Guidelines Working Group: Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 20(Supp 4): iv64–67, 2009

    Article  Google Scholar 

  • Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M. Imatinib plasma levels correlate with clinical benefit in patients with unresectable/metastatic Gastrointestinal Stromal Tumors. J Clin Oncol, 27: 3141–3147, 2009. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.20.4818

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria

    Ferdinand Ploner

  2. Klinische Abteilung für Allgemeinchirurgie, Universitätsklinik für Chirurgie, Medizinische Universität Wien-AKH, Wien, Austria

    Johannes Zacherl

  3. Institut für Klinische Pathologie, Medizinische Universität Wien-AKH, Wien, Austria

    Friedrich Wrba

  4. Abteilung für Allgemeinmedizin, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria

    Friedrich Längle & Evelyne Bareck

  5. Schwerpunkt Onkologie, Universitätsklinik für Innere Medizin I (Stoffwechselerkrankungen, Pulmologie, Infektiologie, Endokrinologie, Rheumatologie und Angiologie), Medizinische Universität Innsbruck, Innsbruck, Austria

    Wolfgang Eisterer

  6. 4. Interne Abteilung, Schwerpunkt Onkologie, Hämatologie und Internistische Onkologie, Nephrologie und Dialyse, Palliativmedizin und Remobilisation/Nachsorge, Klinikum Wels – Grieskirchen, Standort Wels, Austria

    Thomas Kühr

  7. Abteilung für Radiologie und bildgebende Diagnostik, Krankenhaus Göttlicher Heiland, Wien, Austria

    Wolfgang Schima

  8. Klinische Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Austria

    Michael Häfner

  9. Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien-AKH, Wien, Austria

    Thomas Brodowicz

Authors
  1. Ferdinand Ploner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Zacherl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Friedrich Wrba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Friedrich Längle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Evelyne Bareck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wolfgang Eisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Kühr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wolfgang Schima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michael Häfner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thomas Brodowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

für das österreichische GIST-Panel

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ploner, F., Zacherl, J., Wrba, F. et al. Klinische Empfehlungen. Gastrointestinale Stromatumore: Empfehlungen zu Diagnose, Behandlung und Nachsorge in Österreich. Wien Med Wochenschr 159, 370–382 (2009). https://doi.org/10.1007/s10354-009-0685-5

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-009-0685-5

Keywords

Schlüsselwörter

Search

Navigation